In the present study, interestingly, we found that the proteinuria level was not consistent with GalNAc exposure. The level of proteinuria is higher in the less GalNAc exposure group. It is tempting to speculate that patients with lower GalNAc exposure will reach a remission of disease not long after immunosupressive treatment even with heavy proteinuria. For the first time, we herein investigated the GalNAc exposure of serum IgA1 in IgAN patients, and explored its associations with clinical parameters and histological manifestations. Our results indicated that patients of IgAN with higher GalNAc exposure rate have lower proteinuria. However, the GalNAc

selleckchem exposure rate of more than 40% was a risk factor of glomerular sclerosis and tubulointerstitial injury. The GalNAc exposure rate may be used to predict prognosis of IgA nephropathy. Our study had several limitations that should be noted. First, it is only a cross-section study. Second, Chinese patients were the only ethnic group to be studied and finally, it was a single-centre study. Therefore, further prospective and multicenter studies are needed to confirm our results. Meanwhile, whether GalNAc exposure will change along with prognosis of disease will also need further BAY 80-6946 clarification. This work was supported by the fund of National Nature

Science Foundation of China (81100511) and the NSFC of Guangdong province (845100800400162). We are deeply grateful to all the patients who donated blood. “
“Aim:  Minimal-change nephrotic syndrome (MCNS) is characterized by a good response to corticosteroid, but a high incidence of relapse. We compared

the effect of intravenous methylprednisolone pulse plus oral prednisolone therapy (pulse group) with that of conventional oral prednisolone alone therapy (oral group) on the responsiveness and relapse in the first attack of adult-onset MCNS patients. Methods:  Eighty-one adult patients with biopsy-proven MCNS, who were previously untreated and admitted to our hospital with their first attack of nephrotic syndrome, were analyzed retrospectively. They were arbitrarily assigned to either pulse group Edoxaban (n = 29, 1000 mg of methylprednisolone intravenously for 3 days, and then oral prednisolone 30 to 40 mg daily for 4 to 8 weeks) or oral group (n = 52, oral prednisolone 1 mg/kg daily for 4 to 8 weeks). We compared the time to response and relapse between the two groups. Results:  Time to steroid response was significantly shorter in the pulse group compared with the oral group (15.2 ± 10.2 vs 26.7 ± 17.6 days, P = 0.03). In 74 patients who reached remission within 12 weeks (pulse vs oral groups; 86.2% vs 96.2%, ns), the time to relapse was not different between two groups but the relapse rate was significantly higher in the pulse group (pulse vs oral groups; 60% vs 35%, P = 0.038).